The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: A retrospective study involving 49 children

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 12, 2007, Pages 2120-2128

  Ribeiro, Maria João ^a   Boddaert, Nathalie ^b   Bellanné Chantelot, Christine ^c   Bourgeois, Sandrine ^a   Valayannopoulos, Vassili ^b   Delzescaux, Thierry ^a   Jaubert, Francis ^b   Nihoul Fékété, Claire ^b   Brunelle, Francis ^b   De Lonlay, Pascale ^b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

18F Fluoro L DOPA; Hyperinsulinism; PET

Indexed keywords

6 FLUORODOPA F 18; CARBIDOPA; DIAZOXIDE; GLUCAGON; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; TRACER; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORODOPA F 18; UNCLASSIFIED DRUG;

ABDOMINAL SCINTISCANNING; ARTICLE; BLOOD SAMPLING; CARBOHYDRATE INTOLERANCE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERINSULINISM; INFANT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; REMISSION; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; VEIN CATHETERIZATION; EVALUATION; METHODOLOGY; NEWBORN; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PERSISTENT HYPERINSULINEMIA HYPOGLYCEMIA OF INFANCY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 36749056733     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0498-y     Document Type: Article

References (41)

1. Rahier J, Falt K, Muntefering H, Becker K, Gepts W, Falkmer S. The basic structural lesion of persistent neonatal hypoglycemia with hyperinsulinism: deficiency of pancreatic D cells or hyperactivity of B cells? Diabetologia 1984;26:282-9.
2. Goossens A, Gepts W, Saudubray JM, Bonnefont JP, Nihoul-Fekete C, Heitz PU, et al. Diffuse and focal nesidioblastosis. A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol 1989;13:766-75.
3. Sempoux C, Guiot Y, Lefevre A, Nihoul-Fékété C, Jaubert F, Saudubray JM, et al. Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome and keys for differential diagnosis. J Clin Endocrinol Metab 1988;83:1455-61.
4. Menni F, De Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, et al. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 2001;107:476-9.
5. Hirsch HJ, Loo S, Evans N, Crigler JF, Filler RM, Gabbay KH. Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin. N Engl J Med 1977;296:1323-6.
6. Glaser B, Hirsch HJ, Landau H. Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 1993;123:644-50.
7. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637-43.
8. De Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F, et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999;340:1169-75.
9. De Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, et al. Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr 2002;161:37-48.
10. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426-9.
11. Nestorowicz A, Wilson BA, Schoor KP, Inoue H, Glaser B, Landau H, et al. Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet 1996;5:1813-22.
12. De Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, et al. Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 1997;100:802-7.
13. Verkarre V, Fournet JC, De Lonlay P, Gross-Morand MS, Devillers M, Rahier J, et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998;102:1286-91.
14. Fournet JC, Mayaud C, De Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, et al. Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. Am J Pathol 2001;158:2177-84.
15. De Lonlay P, Benelli C, Fouque F, Ganguly A, Aral B, Dionisi-Vici C, et al. Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients. Pediatr Res 2001;50:353-7.
16. Filler RM, Weinberg MJ, Cutz E, Wesson DE, Ehrlich RM. Current status of pancreatectomy for persistent idiopathic neonatal hypoglycemia due to islet cell dysplasia. Prog Pediatr Surg 1991;26:60-75.
17. Fekete CN, De Lonlay P, Jaubert F, Rahier J, Brunelle F, Saudubray. The surgical management of congenital hyperinsulinemic hypoglycemia in infancy. J Pediatr Surg 2004;39:267-9.
18. Thornton PS, MacMullen C, Ganguly A, Ruchelli E, Steinkrauss L, Crane A, et al. Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. Diabetes 2003;52:2403-10.
19. Glaser B, Ryan F, Donath M, Landau H, Stanley CA, Baker L, et al. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes 1999;48:1652-7.
20. Sempoux C, Guiot Y, Dahan K, Moulin P, Stevens M, Lambot V, et al. The focal form of persistent hyperinsulinemic hypoglycemia of infancy: morphological and molecular studies show structural and functional differences with insulinoma. Diabetes 2003;52:784-94.
21. De Lonlay P, Giurgea I, Sempoux C, Touati G, Jaubert F, Rahier J, et al. Dominantly inherited hyperinsulinaemic hypoglycaemia. J Inherit Metab Dis 2005;28:267-76.
22. Brunelle F, Negre V, Barth MO, Fekete CN, Czernichow P, Saudubray JM, et al. Pancreatic venous samplings in infants and children with primary hyperinsulinism. Pediatr Radiol 1989;19:100-3.
23. Dubois J, Brunelle F, Touati G, Sebag G, Nuttin C, Thach T, et al. Hyperinsulinism in children: diagnostic value of pancreatic venous sampling correlated with clinical, pathological and surgical outcome in 25 cases. Pediatr Radiol 1995;25:512-6.
24. Chigot V, De Lonlay P, Nassogne MC, Laborde K, Delagne V, Fournet JC, et al. Pancreatic arterial calcium stimulation in the diagnosis and localisation of persistent hyperinsulinemic hypoglycaemia of infancy. Pediatr Radiol 2001;31:650-5.
25. Giurgea I, Laborde K, Touati G, Bellanne-Chantelot C, Nassogne MC, Sempoux C, et al. Acute insulin responses to calcium and tolbutamide do not differentiate focal from diffuse congenital hyperinsulinism. J Clin Endocrinol Metab 2004;89:925-9.
26. Stanley CA, Thornton PS, Ganguly A, MacMullen C, Underwood P, Bhatia P, et al. Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation. J Clin Endocrinol Metab 2004;89:288-96.
27. Rodriguez MJ, Saura J, Finch CC, Mahy N, Billet EE. Localization of monoamine oxidase A and B in human pancreas, thyroid and adrenal glands. J Histochem Cytochem 2000;48:147-51.
28. 11C-harmine. Nucl Med Biol 2003;30:669-79.
29. Oei HK, Gazdar AF, Minna JD, Weir GC, Baylin SB. Clonal analysis of insulin and somatostatin secretion and L-dopa decarboxylase expression by a rat islet cell tumor. Endocrinology 1983;112:1070-5.
30. Lindstrom P. Aromatic-L-amino-acid decarboxylase activity in mouse pancreatic islets. Biochim Biophys Acta 1986;884:276-81.
31. Borelli MI, Villar MJ, Orezzoli A, Gagliardino JJ. Presence of DOPA decarboxylase and its localisation in adult rat pancreatic islet cells. Diabetes Metab 1997;23:161-3.
32. 18F-fluoro-L-DOPA. J Nucl Med 2005;46:560-6.
33. 18F]fluoro-L-DOPA positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J Clin Endocrinol Metab 2006;291:933-40.
34. 18F-FDG PET/ clinical value in pancreatic lesions-a prospective study with 104 patients. J Nucl Med 2004;45:1279-86.
35. 18F-fluodopa PET Scan. J Pediatr 2007;150:140-5.
36. 18F]-DOPA positron emission tomography. Diabetes 2006;55:13-8.
37. Gilbert JA, Frederick LM, Ames MM. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000;6:4365-72.
38. Gilbert JA, Frederick LM, Pobst LJ, Ames MM. Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines. Biochem Pharmacol 2005;69:1159-66.
39. Asplin CM, Paquette TL, Palmer JP. In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 1981;68:314-8.
40. Moens K, Berger V, Ahn JM, Van Schravendijk C, Hruby VJ, Pipeleers D, et al. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes 2002;51:669-75.
41. Hussain K, Bryan J, Christesen HT, Brusgaard K, Aguilar-Bryan L. Serum glucagon counterregulatory hormonal response to hypoglycemia is blunted in congenital hyperinsulinism. Diabetes 2005;54:2946-51.